Overexpression of the human transmembrane tyrosine kinase growth factor receptor (HER-2), characteristic of the ERBB2 group, has been associated with more aggressive forms of tumor and with resistance to endocrine therapies [26-28]. The gene discussed is ERBB2; the disease is neoplasm.